Market revenue in 2023 | USD 934.1 million |
Market revenue in 2030 | USD 1,286.7 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Percutaneous thrombectomy devices |
Fastest growing segment | Neurovascular Embolectomy Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Embolectomy Devices, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices, Catheter-directed thrombolysis (CDT) devices, Inferior vena cava filters (IVCF) |
Key market players worldwide | Medtronic PLC, Boston Scientific Corp, Teleflex Inc, Edwards Lifesciences Corp, LeMaitre Vascular Inc, Cook Medical, DePuy Synthes, iVascular, Vascular Solutions |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clot management devices market will help companies and investors design strategic landscapes.
Percutaneous thrombectomy devices was the largest segment with a revenue share of 36.16% in 2023. Horizon Databook has segmented the U.S. clot management devices market based on neurovascular embolectomy devices, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (cdt) devices, inferior vena cava filters (ivcf) covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. clot management devices market holds a dominant market share of 87.25% in 2022 owing to factors such as growing healthcare expenditure, product innovation, a favorable medical funding environment, the presence of advanced medical technology, and a growing population susceptible to cardiovascular diseases.
For instance, in February 2022, the Peter G. Peterson Foundation article reported that the U.S. healthcare ecosystem was ranked sixth in the 2021 World Index on Healthcare Innovation. Moreover, in the analysis, the U.S. was ranked 1st in medical scientific advancement.
Several research bodies have highlighted a strong correlation between Coronary Artery Disease (CAD) & increased chances of developing blood clots. Moreover, as per CDC, 1 in 20 people in the U.S. die due to CAD. In addition, as per the National Institutes of Health, an estimated 18.2 million adults in the country have CAD.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. clot management devices market , including forecasts for subscribers. This country databook contains high-level insights into U.S. clot management devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account